Correlation of PD-L1 expression with clinicopathologic and molecular variables and prognosis
| Reference | Ethnicity (location) | No. of subjects | Stage | Positive cases (%) | Clinicopathological variables | Molecular variables | Prognosis | |||
|---|---|---|---|---|---|---|---|---|---|---|
| Total | ADC | SCC | Other | |||||||
| Konishi et al.43 | Japan | 52 | 21 | 31 | 0 | I-IV | 26 (50.0) | NS | N/A | N/A |
| Mu et al.45 | China | 109 | 46 | 63 | I-III | 58 (53.2) | Adenocarcinoma histology: P=0.032 | N/A | Shorter OS (P=0.034) | |
| Chen et al.38 | China | 120 | 50 | 50 | 20 | I-III | 69 (57.5) | Moderate-well differentiation: P=0.035, advanced TNM stage (III): P<0.001 | N/A | Shorter OS (P<0.0001) |
| Chen et al.39 | China | 208 | 46 | 130 | 32 | I-IV | 136 (65.3) | Never smoker: P=0.036 negative LN metastasis: P=0.009 | N/A | N/A |
| Velcheti et al.46 | US, Greece | 544 | 226 | 182 | 50 | I-IV | Greece: 75 (24.9), US: 56 (36.1) | Greek cohort: advanced pathologic stage P=0.011, inflammation P=0.03; Yale cohort: squamous histology P=0.009, Inflammation P<0.001 | N/A | Greece: longer OS (P=0.031), Yale: longer OS (P=0.037) |
| D’Incecco et al.41 | Italy | 125 | 83 | 23 | 19 | IV | 68 (55.3) | Adenocarcinoma histology: P=0.005 | EGFR mutations: P=0.001 | Longer TTP (11.7 vs. 5.7 months, P<0.001), longer OS (21.9 vs. 12.5 months, P=0.09) |
| Azuma et al.35 | Japan | 164 | 114 | 50 | 0 | I-III | 82 (50.0) | Women: P<0.001, never smoker: P<0.001, Adenocarcinoma histology: P<0.001 | EGFR mutations: P<0.001 | Shorter OS (55.9 vs. 72.6 months, P=0.039) |
| Mao et al.44 | China | 128 | 67 | 61 | 0 | I-III | 96 (72.7) | Larger tumor size: P=0.04, nodal involvement: P=0.04, higher stage (stage III): P=0.04 | N/A | Shorter OS (28.7 vs. 60.6 months, P<0.01) |
| Tang et al.18 | China | 170 | 145 | 25 | IIIB-IV | 112 (65.9) | NS | ADC cohort: EGFR mutations P=0.067 | Shorter OS in EGFR wild-type cohort (P=0.029) | |
| Cooper et al.40 | Australia | 678 | 276 | 261 | 131 | I-III | 50 (7.4) | Younger age: P<0.05, poor differentiation: P<0.01 | NS | Longer OS in the overall cohort (113.2 vs. 85.5 moths, P=0.023), SCC (P=0.023) and non-ADC (P<0.01) |
| Boland et al.36 | US | 214 | 0 | 214 | 0 | I-IV | 42 (19.6) | N/A | N/A | No significant associations |
| Kim et al.42 | Korea | 331 | 0 | 331 | 0 | I-III | 89 (26.9) | CD8 TILs: P<0.001, early stage (I, II): P=0.059 | EGFR protein expression: P=0.027 | No significant associations |
| Yang et al.47 | Taipei, China | 163 | 163 | 0 | 0 | I | 65 (39.9) | Poor differentiation: P=0.015, vascular invasion: P=0.038 | NS | Longer RFS (P=0.027) |
| Zhang et al.21 | China | 143 | 143 | 0 | 0 | I-III | 70 (49) | Advanced tumor (T) status (T2-4): P=0.034, node involvement (N1/2): P=0.024, advanced pathologic stage (II-III): P=0.005, solid predominant pattern: P=0.032 | NS | Shorter RFS (P<0.001), shorter OS (P=0.002) |
| Koh et al.19 | Korea | 497 | 497 | 0 | 0 | I-III | 293 (59) | Smoking: P=0.056, poor differentiation: P<0.001, solid or micropapillary pattern: P<0.001, LN metastasis: P=0.006 | ALK+: P=0.054, EGFR protein expression: P<0.001, MET protein expression: P<0.001, MET FISH positivity: P=0.037 | Shorter disease-free survival (P<0.001) |
| Lin et al.20 | China | 56 EGFR-mutated | 56 | 0 | 0 | Advanced | 30 (53.6) | NS | N/A | Greater disease-control rate (P=0.004) and longer PFS (P=0.001) after EGFR TKI therapy and longer OS (P=0.004) |
| Calles et al.37 | US | 114 KRAS-mutated NSCLC | I-IV | 27 (24) | Smoking: P=0.03 advanced stage (IV): P=0.046 | N/A | N/A | |||
N/A: not available; NS: not significant; OS: overall survival; PFS: progression-free survival; RFS: relapse-free survival; TTP: time to progression